Please login to the form below

Not currently logged in
Email:
Password:

asthma drug

This page shows the latest asthma drug news and features for those working in and with pharma, biotech and healthcare.

FDA grants priority review for AZ, Amgen’s tezepelumab for asthma

FDA grants priority review for AZ, Amgen’s tezepelumab for asthma

Drug 'has the potential to transform treatment for a broad population of severe asthma patients'. ... The US Food and Drug Administration (FDA) has accepted AstraZeneca (AZ) and Amgen’s submission for their investigational asthma drug tezepelumab and

Latest news

More from news
Approximately 2 fully matching, plus 126 partially matching documents found.

Latest Intelligence

  • GSK forges ahead with its dynamic COPD and asthma portfolio GSK forges ahead with its dynamic COPD and asthma portfolio

    You would imagine coronavirus would be one of those threats.”. GSK is trialling its biologic anti IL-5 drug mepolizumab, licensed for severe asthma, in eosinophilic COPD with a new phase ... The company is also forging ahead with biologics research in

  • The long and winding road to asthma breakthroughs The long and winding road to asthma breakthroughs

    This was the turning point for the development programme.”. The late nights interrogating the science and unpicking data sets prompted the switch from a drug for the broad asthma community to ... a therapy targeted at a subtype representing around 10%

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Researchers are now trying to identify biomarker-based subgroups and drug combinations to try to improve therapeutic outcomes for patients. ... up innate immune responses, and Cancer Research UK is repurposing an AZ chemokine CCR4 receptor drug (AZD2098)

  • US health reforms US health reforms

    In fact, it’s safe to say most C-suite drug executives would hardly shed a tear upon news of Obamacare’s swift demise. ... To cite just one example, patients with financial need get an 85% discount on the popular asthma drug Advair, and that’s by

  • Building BRICs: pharma's key emerging markets are becoming giants Building BRICs: pharma's key emerging markets are becoming giants

    In April 2013, Novartis was denied patent protection for its cancer drug, Glivec, by the Indian Supreme Court. ... This follows similar patent defeats in India for Pegasys, Roche's hepatitis drug, Merck's asthma treatment, Singulair, Gilead's Viread (HIV)

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Enterprise Therapeutics appoints CEO Enterprise Therapeutics appoints CEO

    He joins the drug discovery firm from Xention Discovery, where he had served as chief scientific officer since co-founding the company in 2002. ... Discovery. Dr Peter Finan, chairman of Enterprise Therapeutics, said: “John's experience in ion channels,

  • Former RBS head takes the reins as GSK chair Former RBS head takes the reins as GSK chair

    the past year, and to develop new products in order to offset the decline of its best-selling asthma drug, Advair, as part of his new remit.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Spirit, an OPEN Health Company

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...